Caxton Associates (New York)’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-36,100
| Closed | -$2.75M | – | 484 |
|
|
2023
Q4 | $2.75M | Hold |
36,100
| – | – | 0.14% | 86 |
|
|
2023
Q3 | $2.5M | Buy |
36,100
+23,203
| +180% | +$1.61M | 0.34% | 52 |
|
|
2023
Q2 | $1.22M | Sell |
12,897
-4,014
| -24% | -$379K | 0.18% | 123 |
|
|
2023
Q1 | $1.4M | Sell |
16,911
-5,489
| -25% | -$454K | 0.21% | 91 |
|
|
2022
Q4 | $1.67M | Buy |
22,400
+5,005
| +29% | +$373K | 0.11% | 48 |
|
|
2022
Q3 | $1.44M | Buy |
+17,395
| New | +$1.44M | 0.19% | 42 |
|
|
2021
Q4 | – | Sell |
-3,604
| Closed | -$408K | – | 562 |
|
|
2021
Q3 | $408K | Sell |
3,604
-614
| -15% | -$69.5K | 0.05% | 223 |
|
|
2021
Q2 | $437K | Buy |
+4,218
| New | +$437K | 0.05% | 188 |
|
|
2020
Q4 | – | Sell |
-4,664
| Closed | -$372K | – | 173 |
|
|
2020
Q3 | $372K | Buy |
+4,664
| New | +$372K | 0.04% | 148 |
|
|
2020
Q2 | – | Sell |
-9,807
| Closed | -$617K | – | 495 |
|
|
2020
Q1 | $617K | Buy |
9,807
+2,799
| +40% | +$176K | 0.11% | 115 |
|
|
2019
Q4 | $545K | Buy |
+7,008
| New | +$545K | 0.07% | 153 |
|
|
2019
Q1 | – | Sell |
-5,145
| Closed | -$263K | – | 405 |
|
|
2018
Q4 | $263K | Sell |
5,145
-5,394
| -51% | -$276K | 0.04% | 195 |
|
|
2018
Q3 | $612K | Hold |
10,539
| – | – | 0.04% | 157 |
|
|
2018
Q2 | $511K | Buy |
10,539
+726
| +7% | +$35.2K | 0.03% | 198 |
|
|
2018
Q1 | $456K | Buy |
+9,813
| New | +$456K | 0.02% | 226 |
|